Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic

Biomaterials

Volumn 82, Issue , 2016, Pages 178-193

  Au, Kin Man ^a,b   Satterlee, Andrew ^c   Min, Yuanzeng ^a,b   Tian, Xi ^a,b   Kim, Young Seok ^a,b,d   Caster, Joseph M ^a,b   Zhang, Longzhen ^e   Zhang, Tian ^f   Huang, Leaf ^c   Wang, Andrew Z ^a,b,e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d University of Ulsan College of Medicine   (South Korea)

^e XUZHOU MEDICAL UNIVERSITY   (China)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Chemotherapy; Drug delivery; Folate targeted nanoscale metal organic frameworks; Zoledronate

Indexed keywords

BIOLOGICAL ORGANS; BONE; CALCIUM; CELL DEATH; CELL PROLIFERATION; CHEMICAL STABILITY; CHEMOTHERAPY; CRYSTALLINE MATERIALS; CYTOLOGY; CYTOTOXICITY; DISEASES; DRUG DELIVERY; MOLECULAR BIOLOGY; NANOTECHNOLOGY; ORGANOMETALLICS; TUMORS; UROLOGY;

ANTI-TUMOR ACTIVITIES; CANCER; CHEMICAL AND COLLOIDAL STABILITIES; NANOSCALE METALS; NON SMALL CELL LUNG CANCER; PHYSIOLOGICAL CONDITION; PROSTATE CANCER CELLS; ZOLEDRONATE;

CELLS;

CALCIUM; CASPASE 3; FOLATE RECEPTOR; FOLIC ACID; LIPOSOME; MACROGOL; METAL ORGANIC FRAMEWORK; WATER OIL CREAM; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DELAYED RELEASE FORMULATION; IMIDAZOLE DERIVATIVE; METAL; NANOCAPSULE; NANOCOMPOSITE; ORGANIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENCAPSULATION; ENDOCYTOSIS; ENDOSOME; ENZYME ACTIVITY; EX VIVO STUDY; FLUORESCENCE IMAGING; HISTOPATHOLOGY; HYDROPHOBICITY; IMMUNOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; IONIC STRENGTH; MALE; MICROEMULSION; MOUSE; NANOTECHNOLOGY; NONHUMAN; PH; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTON TRANSPORT; ROENTGEN SPECTROSCOPY; SURFACE PROPERTY; SYNTHESIS; THERMAL ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; X RAY POWDER DIFFRACTION; ADMINISTRATION AND DOSAGE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; HUMAN; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DIPHOSPHONATES; FOLIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; METALS; NANOCAPSULES; NANOCOMPOSITES; NEOPLASMS, EXPERIMENTAL; ORGANIC CHEMICALS; TREATMENT OUTCOME;

EID: 84957540689     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.12.018     Document Type: Article

References (51)

1. Green J.R. Bisphosphonates: preclinical review. Oncologist 2004, 9(Suppl. 4):3-13.
2. Berenson J.R., Rosen L.S., Howell A., Porter L., Coleman R.E., Morley W., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001, 91:1191-1200.
3. McKeage K., Plosker G.L. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics 2008, 26:251-268.
4. Almubarak H., Jones A., Chaisuparat R., Zhang M., Meiller T.F., Scheper M.A. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J. Carcinog. 2011, 10:2.
5. Zekri J., Mansour M., Karim S.M. The anti-tumor effects of zoledronic acid. Oncology 2014, 2:25-35.
6. Russell R.G., Rogers M.J., Frith J.C., Luckman S.P., Coxon F.P., Benford H.L., et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J. Bone Min. Res. 1999, 14(Suppl. 2):53-65.
7. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Broadley K.E., Johnston S.R. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003, 327:469.
8. Tsagozis P., Eriksson F., Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol. Immunother. 2008, 57:1451-1459.
9. McClung M. Bisphosphonates. Arq. Bras. Endocrinol. Metabol. 2006, 50:735-744.
10. Park J., Matralis A.N., Berghuis A.M., Tsantrizos Y.S. Human isoprenoid synthase enzymes as therapeutic targets. Front. Chem. 2014, 2:50.
11. Santini D., Vincenzi B., Galluzzo S., Battistoni F., Rocci L., Venditti O., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 2007, 13:4482-4486.
12. Wood J., Bonjean K., Ruetz S., Bellahcène A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 2002, 302:1055-1061.
13. Early Breast Cancer Trialists Colloborative Group (EBCTCG) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015, 386:1353-1361.
14. De Rosa G., Misso G., Salzano G., Caraglia M. Bisphosphonates and cancer: what opportunities from nanotechnology?. J. Drug Deliv. 2013, 2013:637976.
15. Marra M., Salzano G., Leonetti C., Tassone P., Scarsella M., Zappavigna S., et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 2011, 7:955-964.
16. Shmeeda H., Amitay Y., Tzemach D., Gorin J., Gabizon A. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. J. Control Release 2013, 167:265-275.
17. Liu D., Kramer S.A., Huxford-Phillips R.C., Wang S., Della Rocca J., Lin W. Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers. Chem. Commun. (Camb.) 2012, 48:2668-2670.
18. Xia W., Low P.S. Folate-targeted therapies for cancer. J. Med. Chem. 2010, 53:6811-6824.
19. Cal P.M., Frade R.F., Chudasama V., Cordeiro C., Caddick S., Gois P.M. Targeting cancer cells with folic acid-iminoboronate fluorescent conjugates. Chem. Commun. (Camb.) 2014, 50:5261-5263.
20. Yao V., Berkman C.E., Choi J.K., O'Keefe D.S., Bacich D.J. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 2010, 70:305-316.
21. Berenson J.R., Vescio R.A., Rosen L.S., VonTeichert J.M., Woo M., Swift R., et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin. Cancer Res. 2001, 7:478-485.
22. Berenson J.R., Vescio R., Henick K., Nishikubo C., Rettig M., Swift R.A., et al. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001, 91:144-154.
23. Goldsmith M.A., Slavik M., Carter S.K. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res. 1975, 35:1354-1364.
24. Mason K.A., Hunter N.R., Milas M., Abbruzzese J.L., Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin. Cancer Res. 1997, 3:2431-2438.
25. Rosenzweig K.E., Youmell M.B., Palayoor S.T., Price B.D. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin. Cancer Res. 1997, 3:1149-1156.
26. Li J., Yang Y., Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control Release 2012, 158:108-114.
27. Destrée C., Debuigne F., Jeunieau L., Nagy J.B. Mechanism of formation of inorganic and organic nanoparticles from microemulsions. Adv. Colloid Interface Sci. 2006, 123-126:353-367.
28. Li J., Chen Y.C., Tseng Y.C., Mozumdar S., Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control Release 2010, 142:416-421.
29. Lu H.B., Campbell C.T., Graham D.J., Ratner B.D. Surface charactization of hydroxyapatite and related calcium phosphates by XPS and TOF-SIMS. Anal. Chem. 2000, 72:2886-2894.
30. Pascaud P., Bareille R., Bourget C., Amédée J., Rey C., Sarda S. Interaction between a bisphosphonate, tiludronate and nanocrystalline apatite: in vitro viability and proliferation of HOP and HBMSC cells. Biomed. Mater. 2012, 7:054108.
31. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-237.
32. Liu D., Poon C., Lu K., He C., Lin W. Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat. Commun. 2014, 5:4182.
33. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
34. Glausch Alexandra LR, Sigg Juergen. Pharmaceutical Products Comprising Bisphosphonate. In: (CH) NA, editor. DE2004.
35. Geisow M.J., Evans W.H. pH in the endosome. Measurements during pinocytosis and receptor-mediated endocytosis. Exp. Cell Res. 1984, 150:36-46.
36. Kester M., Heakal Y., Fox T., Sharma A., Robertson G.P., Morgan T.T., et al. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett. 2008, 8:4116-4121.
37. Muddana H.S., Morgan T.T., Adair J.H., Butler P.J. Photophysics of Cy3-encapsulated calcium phosphate nanoparticles. Nano Lett. 2009, 9:1559-1566.
38. Hirst R.A., Harrison C., Hirota K., Lambert D.G. Measurement of [Ca2+]i in whole cell suspensions using fura-2. Methods Mol. Biol. 2006, 312:37-45.
39. Porter A.G., Jänicke R.U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999, 6:99-104.
40. Liu Y., Tseng Y.C., Huang L. Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method?. Pharm. Res. 2012, 29:3273-3277.
41. Berenson J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005, 10:52-62.
42. Ashihara E., Munaka T., Kimura S., Nakagawa S., Nakagawa Y., Kanai M., et al. Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells. Biochem. Biophys. Res. Commun. 2015, 463:650-655.
43. Morag Y., Morag-Hezroni M., Jamadar D.A., Ward B.B., Jacobson J.A., Zwetchkenbaum S.R., et al. Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. Radiographics 2009, 29:1971-1984.
44. Chang J.T., Green L., Beitz J. Renal failure with the use of zoledronic acid. N. Engl. J. Med. 2003, 349:1676-1679. discussion -9.
45. Baluk P., Morikawa S., Haskell A., Mancuso M., McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2003, 163:1801-1815.
46. Strzalka W., Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Ann. Bot. 2011, 107:1127-1140.
47. ®-the first FDA-approved nano-drug: lessons learned. J. Control Release 2012, 160:117-134.
48. Sethi M., Sukumar R., Karve S., Werner M.E., Wang E.C., Moore D.T., et al. Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity. Nanoscale 2014, 6:2321-2327.
49. Morgan T.T., Muddana H.S., Altinoglu E.I., Rouse S.M., Tabaković A., Tabouillot T., et al. Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Lett. 2008, 8:4108-4115.
50. Tseng Y.C., Yang A., Huang L. How does the cell overcome LCP nanoparticle-induced calcium toxicity?. Mol. Pharm. 2013, 10:4391-4395.
51. Tannock I.F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989, 49:4373-4384.